Physician profile
Brice B Dille
NPI 1437151990
$5,614.61
in general payments reported to CMS, 2019-2025
29 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $302 · 2021: $746 · 2022: $579 · 2023: $1,234 · 2024: $1,077 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,393.58 | 2019-2025 | Clareon, Argos, Ngenuity |
| Sun Pharmaceutical Industries INC. | $577.60 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $349.97 | 2023-2025 | Combigan, Restasis Multidose, Vuity |
| Mallinckrodt Hospital Products INC. | $256.49 | 2020-2025 | Acthar |
| Sight Sciences, INC. | $196.53 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $180.23 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $177.45 | 2025 | |
| New World Medical,INC. | $163.18 | 2023-2025 | Streamline, Via360, Clearpath |
| Allergan, INC. | $153.95 | 2019-2022 | |
| Glaukos Corporation | $144.09 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $120.51 | 2024-2025 | Xdemvy |
| Omeros Corporation | $103.62 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $83.82 | 2022-2024 | Vyzulta, Miebo |
| Rxsight INC | $82.55 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Mallinckrodt Enterprises LLC | $81.81 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $75.05 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $62.75 | 2023-2025 | Tyrvaya |
| Ivantis, INC | $59.38 | 2020-2021 | |
| Inari Medical, INC. | $56.11 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Johnson & Johnson Surgical Vision, INC. | $55.16 | 2019 | |
| Kala Pharmaceuticals, INC. | $47.17 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.07 | 2019 | |
| Ocular Therapeutix, INC. | $29.03 | 2021 | |
| Shire North American Group INC | $27.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.13 | 2019-2021 | |
| Horizon Therapeutics Plc | $19.70 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $19.33 | 2022 | |
| Rayner Intraocular Lenses Limited | $18.43 | 2022 | |
| Spark Therapeutics, INC. | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brice Dille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.